| Beacon Medical Group Bristol | |
|
306 E Vistula Bristol IN 46507-9489 | |
| (574) 848-4427 | |
| (574) 848-4592 |
| Full Name | Beacon Medical Group Bristol |
|---|---|
| Speciality | Family Medicine |
| Location | 306 E Vistula, Bristol, Indiana |
| Authorized Official Name and Position | Jeffrey P Costello (CFO) |
| Authorized Official Contact | 5746473549 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Beacon Medical Group Bristol 710 N Niles Ave South Bend IN 46617-1924 Ph: (574) 647-1610 | Beacon Medical Group Bristol 306 E Vistula Bristol IN 46507-9489 Ph: (574) 848-4427 |
| NPI Number | 1447285697 |
|---|---|
| Provider Enumeration Date | 07/12/2006 |
| Last Update Date | 04/24/2023 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447285697 | NPI | - | NPPES |
| 000000110755 | Other | IN | BCBS REMIT |
| 100114000B | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 06-005017-1 (Indiana) | Primary |
News Archive
Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions , as reported in the July 2013 issue of The Joint Commission Journal on Quality and Patient Safety.
As a protest against the Queensland government's pay offer, thousands of health workers plan to stop work in Brisbane on Thursday. This would include health practitioners, psychologists, physiotherapists, radiographers and scientists. The rally would take place outside Parliament House in Brisbane at noon. The outrage followed the state government's 2.5 per cent a year pay rise offer over three years.
Now, a new study published in the journal Signal Transduction and Targeted Therapy in August 2020 shows that while humoral and T-cell immune responses are more robust in severe infection, the disease activates memory T cells as part of the adaptive immune system in COVID-19 patients irrespective of disease severity.
Eli Lilly and Company today announced that it is providing more than $4 million in additional funding to the Infectious Disease Research Institute. The funding will allow IDRI to continue its early phase drug discovery efforts focused on identifying new and better therapies in the fight against tuberculosis, including multidrug-resistant strains known as MDR-TB.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.
› Verified 2 days ago